SCHEMBL17209754

SCHEMBL17209754

Cc1ccc2cc(C(=O)NC3CCCCCCC3)[nH]c2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLLT1 Q03111 1/20 0.60
NPC1 O15118 4/20 0.56
RAB9A P51151 4/20 0.56
CYP1A2 P05177 1/20 0.54
HPGD P15428 1/20 0.54
CYP2C19 P33261 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
ITK Q08881 1/20 0.50
KDM4E B2RXH2 1/20 0.50
F12 P00748 1/20 0.49
TAS1R3 Q7RTX0 2/20 0.49
TAS1R1 Q7RTX1 2/20 0.49
TAS1R2 Q8TE23 2/20 0.49
ADORA1 P30542 1/20 0.48
TP53 P04637 1/20 0.48
HTT P42858 1/20 0.48
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
SMYD3 Q9H7B4 2/20 0.47
FLT3 P36888 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17209759 0.90 MLLT1 (0.70) MLLT1NPC1RAB9ACYP1A2HPGD
SCHEMBL11888227 0.90 MLLT1 (0.70) MLLT1NPC1RAB9ACYP1A2HPGD
SCHEMBL17209760 0.90 MLLT1 (0.70) MLLT1NPC1RAB9ACYP1A2HPGD
SCHEMBL11888208 0.88 MLLT1 (0.72) MLLT1NPC1RAB9ACYP1A2HPGD
SCHEMBL29176357 0.84 MLLT1 (0.60) MLLT1NPC1RAB9AHTTSMYD3
SCHEMBL18183271 0.84 MLLT1 (0.60) MLLT1NPC1RAB9AHTTSMYD3
SCHEMBL15506758 0.84 NPC1 (0.56) MLLT1NPC1RAB9AHPGDKDM4E
SCHEMBL15506687 0.84 TAS1R3 (0.53) MLLT1SMN1; SMN2KDM4ETAS1R3TAS1R1
SCHEMBL29176327 0.83 MLLT1 (0.61) MLLT1NPC1RAB9ASMYD3PLA2G7
SCHEMBL74244 0.82 MLLT1 (0.67) MLLT1NPC1RAB9AHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170044100-A1 INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS UNIV JOHNS HOPKINS (US) 2017-02-16 US disclosed
US-20170044100-A1 INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS UNIV JOHNS HOPKINS (US) 2017-02-16 US disclosed
WO-2016171743-A1 INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS THE JOHNS HOPKINS UNIVERSITY (US) 2016-10-27 WO disclosed
WO-2015164482-A1 INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS THE JOHNS HOPKINS UNIVERSITY (US) 2015-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044100-A1 INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS IDO2, IDO1, INMT MLLT1 399/4885NPC1 2930/4885RAB9A 3348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.